Sotalol
- Generic Name
- Sotalol
- Brand Names
- Betapace, Sorine, Sotylize
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N2O3S
- CAS Number
- 3930-20-9
- Unique Ingredient Identifier
- A6D97U294I
- Background
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal ...
- Indication
Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter. There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.
- Associated Conditions
- Sinus Rhythm, Life-threatening ventricular arrhythmias
- Associated Therapies
- -
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
- Conditions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87810
- Registration Number
- NCT05279833
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Samir Saba
- Target Recruit Count
- 12
- Registration Number
- NCT04128878
- Locations
- 🇺🇸
University of Pittsburgh Medical Center - Presbyterian University Hospital, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Sotalol in Children With Arrhythmia
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03895411
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Maatschap Cardiologie Zwolle
- Target Recruit Count
- 22
- Registration Number
- NCT03845010
- Locations
- 🇳🇱
Isala hospital, Zwolle, Netherlands
Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 36
- Registration Number
- NCT03799536
- Locations
- 🇧🇾
National Anti-Doping Laboratory, Settl.Lesnoy, Minsk Region, Belarus
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 162
- Registration Number
- NCT02347111
- Locations
- 🇺🇸
Jesse Brown VA Medical Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT02294955
- Locations
- 🇸🇪
Carina Blomström Lundqvist, Uppsala, Sweden
Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT02153437
- Locations
- 🇨🇦
Local Institution - 0001, Toronto, Ontario, Canada
🇨🇦Local Institution, Montreal, Quebec, Canada
🇨🇦The University Of Calgary, Calgary, Alberta, Canada
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2014-05-23
- Target Recruit Count
- 600
- Registration Number
- NCT02145546
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai Jiao Tong University School of Medicne, Shanghai, Shanghai, China
Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator
- Conditions
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 27
- Registration Number
- NCT01576042
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.